3-Bromo-6-chloro-2-methylpyridine

We are 3-Bromo-6-chloro-2-methylpyridine CAS:132606-40-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:    3-Bromo-6-chloro-2-methylpyridine
CAS.NO:132606-40-7
Synonyms:  3-Bromo-6-chloro-2-methylpyridine
5-Bromo-2-chloro-6-methylpyridine
3-Bromo-6-chloro-2-picoline
3-Bromo-6-Chloro-2-Methylpyridine
 
Molecular Formula:C6H5BrClN
Molecular Weight:206.46800
 
Physical and Chemical Properties:
Density:1.624g/cm3
Boiling point:220.6ºC at 760mmHg
Melting point:<40ºC
Flash point:87.2ºC
Index of Refraction:1.571
 
Specification:
Appearance:Yellow liquid
Purity:≥99.0%
 
Packing:25kg/drum, can also be packaged according to customer requirements
Storage:Preserve in well-closed, light-resistant and airtight containers
Application: Pesticide intermediates, dye intermediates, flavor and fragrance intermediates, pharmaceutical intermediates

3-Bromo-6-chloro-2-methylpyridine


Related News: Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.791-31-1;16527-35-8 According to statistics, in the ten years from 2008 to 2017, a total of 13 “China Class 1” small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China.3-isocyanatopropyl(trimethoxy)silane Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.N- (5-cloro-2-metoxifenil) -3-hidroxinaftaleno-2-carboxamida CAS:137-52-0 The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.“We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”

Related Products
Product Name
Pentafluorophenol View Details
Dichlorodimethylsilane View Details
3,5-Dimethylbenzonitrile View Details
(4S,5R)-3-Benzoyl-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid manufacturer Octahydro-1H-indole-2-carboxylic acid manufacturer 2-Bromo-3-methylbenzoic acid manufacturer 3,4-Dichlorophenylboronic acid manufacturer 5-Amino-2-chloropyridine manufacturer